Miels succeeded Emma Walmsley to become GSK’s new CEO at the beginning of 2026, inheriting the role as GSK posted what he ...

Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest. | Luke Miels had only ...

GSK (NYSE:GSK) executives struck an upbeat tone on the company’s full-year 2025 results call, pointing to broad-based sales growth, operating leverage, and a pipeline they said is gaining momentum.

GSK has agreed to acquire RAPT Therapeutics, adding food allergy drug candidates to its pipeline. The company has received ...

British pharmaceutical group GSK reported Wednesday a sharp rise in annual net profit, boosted by strong sales of HIV, ...